Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of SD-101 cream in epidermolysis bullosa
NL-OMON44714Phase 3Active, not recruiting
- Sponsor
- Scioderm
- Start
- Mar 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epidermolysis bullosa (EB), epidermolysis bullosa simplex (EBS) and Recessive Dystrophic Epidermolysis Bullosa (RDEB) comparing SD-101 cream with Placebo cream (2 arms). Primary endpoints: Time to complete target wound closure within 3 months and Proportion of patients with complete target wound closure within 3 months. Started Mar 2015; status: active, not recruiting.
02
Drugs
nelitolimod
03
Conditions
epidermolysis bullosa (EB)epidermolysis bullosa simplex (EBS)Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Beyond the preview
Go deeper on NL-OMON44714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44714.